ABSTRACT
Subclinical malaria may reduce the immunogenicity of mRNA vaccines. We evaluated neutralizing antibody responses in adults with (n=87) and without (n=221) PCR-confirmed Plasmodium falciparum who received a COVID-19 booster. Similar boosted ID50 geometric mean titers >22,000 in parasitemic and non-parasitemic participants suggests that COVID-19 mRNA vaccine responses are not impaired.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05168813
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) grants (grant numbers UM1 AI068614-14 [HVTN/CoVPN LOC], UM1 AI068635 [HVTN/CoVPN SDMC], 3UM1AI068618-15S1 [HVTN/CoVPN LC], and T32AI007044-45 [Dr. Tapley]). NIAID co-authors were part of the CoVPN 3008 PSRT for safety supervision. Support for PATH authors and malaria PCR testing were provided through a grant to PATH from the Gates Foundation (INV007217). The funders had no role in data collection and analysis, or the decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kenya Medical Research Institute's (KEMRI) ethics committee, Scientific Ethics Review Unit (SERU), gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors have declared that no conflict of interest exists.
Data Availability
This study accesses data through the HIV Vaccine Trials Network (HVTN). Permission to access data will have toshould be requested from HVTN and the Statistical Center for HIV/AIDS Research & Prevention (SCHARP).
